Cholangiocellular Hepatoma - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 15

Cholangiocellular Hepatoma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Cholangiocellular Hepatoma - Pipeline Review, H2 2012', provides an overview of the Cholangiocellular Hepatoma therapeutic pipeline. This report provides information on the therapeutic development for Cholangiocellular Hepatoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cholangiocellular Hepatoma. 'Cholangiocellular Hepatoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cholangiocellular Hepatoma.
- A review of the Cholangiocellular Hepatoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cholangiocellular Hepatoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cholangiocellular Hepatoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cholangiocellular Hepatoma pipeline depth and focus of Cholangiocellular Hepatoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Cholangiocellular Hepatoma Therapeutic Products under Development, Key Players in Cholangiocellular Hepatoma Therapeutics, Cholangiocellular Hepatoma Pipeline Overview, Cholangiocellular Hepatoma Pipeline, Cholangiocellular Hepatoma Pipeline Assessment

2
List of Tables 3
List of Figures 3
Introduction 4
REPORT COVERAGE 4
Cholangiocellular Hepatoma Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Cholangiocellular Hepatoma 6
Late Stage Products 8
Comparative Analysis 8
Cholangiocellular Hepatoma Therapeutics – Products under Investigation by Universities/Institutes 9
Assessment by Combination Products 10
Assessment by Molecule Type 11
Drug Profiles 13
Cisplatin + Gemcitabine + Epirubicin - Drug Profile 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Appendix 14
Methodology 14
Coverage 14
Secondary Research 14
Primary Research 14
Expert Panel Validation 14
Contact Us 15
Disclaimer 15

List of Tables
Number of Products Under Development for Cholangiocellular Hepatoma, H2 2012 6
Products under Development for Cholangiocellular Hepatoma – Comparative Analysis, H2 2012 7
Comparative Analysis by Late Stage Development, H2 2012 8
Products under Investigation by Universities/Institutes, H2 2012 9
Assessment by Combination Products, H2 2012 10
Assessment by Stage and Molecule Type, H2 2012 12

List of Figures
Number of Products under Development for Cholangiocellular Hepatoma, H2 2012 6
Products under Development for Cholangiocellular Hepatoma – Comparative Analysis, H2 2012 7
Late Stage Products, H2 2012 8
Assessment by Combination Products, H2 2012 10
Assessment by Molecule Type, H2 2012 11
Assessment by Stage and Molecule Type, H2 2012 12

Customers who bought this item also bought

• Acute Pain - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012
• Pulmonary Fibrosis - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Male Cancer - Pipeline Review, H2 2012
• Osteoarthritis - Pipeline Review, H2 2012
• Epilepsy - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012
• Type 2 Diabetes - Pipeline Review, H2 2012